Drug intelligence / Profile preview

paracetamol + metoclopramide

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Paracetamol + metoclopramide is a fixed-dose oral combination medication used primarily for the treatment of migraine attacks. Paracetamol acts as an analgesic and antipyretic, providing pain relief by inhibiting prostaglandin synthesis in the central nervous system. Metoclopramide is a dopamine D2 receptor antagonist with antiemetic and prokinetic properties; it alleviates nausea and vomiting associated with migraines by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, antagonizing serotonin 5-HT3 receptors, agonizing serotonin 5-HT4 receptors, and enhancing gastric motility. The combination not only relieves headache but also addresses delayed gastric emptying often seen during migraine attacks, potentially improving absorption of paracetamol[1][2][4][5].

Brand names
ParamaxMigraeflux MCPMeteclomaxAnagrainePRIMADOL
Other names
paracetamol/metoclopramide hydrochloride
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)HTR4 (5-Hydroxytryptamine receptor 4)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on paracetamol + metoclopramide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + metoclopramide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call